• August 03, 2020

New Brain Cancer Treatment Leads To Extended Survival Of Patients

A promising new brain cancer treatment  with an aggressive form of brain cancer has been found to the extend survival and longevity for years a team of the researchers from the United States revealed.Doctors from the University of California Los Angeles UC San Diego and Cleveland Clinic injected patients who had recurrent glioblastoma ,brain cancer treatment is hard with a genetically engineered virus during the phase 1 study. Glioblastoma is the most deadly of all kinds of the brain cancer. Often if the tumor recurs even after radiation and chemotherapy there are few treatment options left and patients only have a few months to live.

Now, in the new study experts found that among the 43 patients given the treatment called Toca 511 and Toca FC, survival increased by 13.6 months compared to 7.1 months in an extended control.Survival increased by more than two years for 42 percent of the participants, albeit with side effects.The new report which was led by Timothy Cloughesy of UCLA is the first published data on the new type of modified virus called retroviral replicating vector (RRV).

As the gene moves throughout the tumor, Toca 511 “orders” the cancer cell to produce CD. Once the cancer cells obey, they are prepared for the second step.Patients then receive oral cycle of the antifungal drug Toca FC for seven days every four to eight weeks.Toca 511 has already caused genetic changes in the tumor, and so this will allow infected cancer cells to turn Toca FC into the anticancer drug 5-fluorouracil (5-FU), which has been approved by the Food and Drug Administration (FDA).As a result, cancer cells and immunosuppressive cells infected by both treatments are selectively killed, activating the immune system to recognize and target cancer cells while leaving healthy cells unharmed.Meanwhile, Cloughesy says the use of RRVs shows promise in the development of new therapies for all kinds of brain cancer. It may also be applied in treatment for metastatic breast and colorectal cancers.

About the Author